According to a research report by IMARC Group, the global medical cannabis market size reached USD 39.6 Billion in 2025. The market is projected to reach USD 74.3 Billion by 2034, exhibiting a growth rate (CAGR) of 6.90% during 2026–2034. The market is primarily driven by the increasing product use in treating substance use disorders, the exploration of products for chronic inflammatory conditions, rising demand for CBD-based products, and the growing acceptance of cannabis for medicinal purposes across global markets.

Market at a Glance

Request for a Sample Report for Detailed Evaluation: https://www.imarcgroup.com/medical-cannabis-market/requestsample

Key Medical Cannabis Market Trends Driving Expansion

Rising Clinical Trials, R&D Activities, and Commercialization of Cannabis-Based Indications

The market is expected to grow due to an increase in the number of clinical trials‚ R&D‚ and commercialization of cannabis-based indications․ Furthermore‚ increasing acceptance and legalization of cannabis have created a platform for researchers‚ pharmaceutical companies‚ and healthcare professionals to conduct R&D regarding the therapeutic benefits of the product․ Medicinal cannabis‚ pharmaceutical cannabis‚ or medical marijuana‚ is used in clinical trials and research studies to provide evidence for the therapeutic and non-therapeutic effects of cannabis-based medicines and their pharmacological products for the treatment of numerous diseases․ The commercial potential of cannabis-based medicines has led to large investments by pharmaceutical companies and cannabis-based companies․ Commercialized‚ regulated pharmaceutical-grade cannabis products provide standardized dosing and consistent effects․

Inflating Disposable Incomes of Consumers

One of the factors that drive the market's growth is the rise in the disposable income․ A disposable income allows a consumer to spend more on healthcare services like alternative and complementary medicine․ The financial resources available to individuals may also increase the interest and use of medical cannabis for more health conditions․ In some jurisdictions‚ medical cannabis is not covered by health insurance‚ and those with higher incomes have a greater opportunity to investigate its use․ This increase in disposable income enables the consumers to choose premium products which are generally manufactured by branded players and hence is one of the key drivers for the growth of the premium segment․

Emergence of New Cannabis-Based Pharmaceutical Products

New cannabis-based prescription pharmaceutical drugs will help to drive market growth․ Clinical trials and research are providing better understanding of potential helpful effects of cannabinoids and other compounds found in cannabis‚ while pharmaceutical companies are launching cannabis-based drugs after wide-ranging testing and regulatory approvals that help to drive consumption rates․ The development of standardized cannabis-based medications will help to assure both patients and practitioners‚ and as further cannabis-based medicines are developed‚ it is likely that these products will be used for the treatment of a wider variety of conditions including chronic pain‚ neurological disorders‚ and mental disorders․

Growing Prevalence of Chronic Pain and Age-Related Conditions

The rising prevalence of chronic pain and other disorders for which medical cannabis can be used‚ continued growth in the aging population with a need for alternative treatment methods for age-related diseases such as arthritis‚ neuropathy and sleep apnea‚ and the opioid crisis and need for safer alternatives to opioids for pain treatment are expected to support growth in the market for medical cannabis․ Medical cannabis is a plant-based alternative‚ considered to have a superior safety profile․ Increased knowledge regarding the therapeutic potential of cannabinoids is helping in both the prescriber's and patient's acceptance of cannabinoid therapy.

Medical Cannabis Market Segmentation Analysis

By Species

• Indica
• Sativa
• Hybrid

Indica dominates the market - as Cannabis indica is known for its high CBD content and relatively lower THC levels, aligning well with the rising interest in CBD-based therapeutic applications. Indica's relaxing and sedative properties make it appealing for medicinal use in addressing sleep disorders, anxiety, and inflammation, without inducing the strong psychoactive effects commonly associated with THC. The evolving legal landscape and greater acceptance of medical cannabis have further contributed to the market growth of Cannabis indica products as patients and healthcare professionals increasingly adopt these strains.

By Derivatives

• Cannabidiol (CBD)
• Tetrahydrocannabinol (THC)
• Others

Tetrahydrocannabinol (THC) dominates the market - as one of the primary cannabinoids in cannabis, THC interacts with the body's endocannabinoid system to produce various physiological and psychological effects. Patients with chronic pain, cancer-related symptoms, and multiple sclerosis find THC-containing medical cannabis products beneficial in managing their conditions. Furthermore, the broader recreational use of THC has helped destigmatize cannabis overall, leading to increased acceptance and legalization in various regions, which in turn has contributed to the market growth of medical cannabis and made it more accessible to patients in need.

By Application

• Cancer
• Arthritis
• Migraine
• Epilepsy
• Others

Cancer dominates the market - due to medical cannabis's potential to manage cancer-related symptoms and side effects of cancer treatments. Medical cannabis has shown promise in alleviating chemotherapy-induced nausea and vomiting, stimulating appetite in patients experiencing cachexia, and providing analgesic benefits for cancer-related pain management. Moreover, medical cannabis may possess anti-inflammatory and anti-tumor properties, sparking interest in its potential role as an adjunct therapy in cancer treatment. The growing number of cancer patients and increasing acceptance of medical cannabis as a complementary treatment option continue to contribute to market growth.

By End-Use

• Pharmaceutical Industry
• Research and Development Centres
• Others

The pharmaceutical industry dominates the market - through extensive research and development and commercialization of cannabis-based medications. Pharmaceutical companies are investing in clinical trials to develop novel cannabis-based pharmaceutical products across various delivery methods, formulations, and dosages. By developing pharmaceutical-grade cannabis products, they address concerns about consistency, safety, and efficacy — essential for medical professionals and patients. Furthermore, the pharmaceutical industry's involvement brings credibility and legitimacy to the sector, encouraging wider acceptance and driving the integration of cannabis-based treatments into mainstream medicine.

By Route of Administration

• Oral Solutions and Capsules
• Vaporizers
• Topicals
• Others

Oral solutions and capsules dominate the market - owing to their convenience, dosage accuracy, and ease of administration. As pharmaceutical companies develop standardized cannabis-based medications in these forms, patients can consume medical cannabis more discreetly and precisely, with consistent dosing that makes it easier for healthcare professionals to prescribe and monitor patient treatment. These delivery methods particularly appeal to older adults and individuals seeking a smoke-free, non-inhalation approach to medical cannabis consumption, contributing to better patient compliance and more successful treatment outcomes.

By Region

• North America (United States, Canada)
• Asia Pacific
• Europe (Germany, France, Italy, Spain, Netherlands)
• Latin America
• Middle East and Africa

North America exhibits a clear dominance, accounting for the largest medical cannabis market share - driven by a progressive regulatory environment, increasing acceptance, and widespread legalization across various states and provinces. The United States and Canada have been at the forefront of the medical cannabis movement, with growing awareness and patient demand spurring investments in research, development, and commercialization. Well-established pharmaceutical companies and research institutions in North America have accelerated the development of standardized and regulated cannabis-based medications, while supportive healthcare policies and a strong consumer base further position the region as a significant driving force behind the market's global growth.

Connect for Detailed Segmentation Analysis - Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=1053&flag=C

Competitive Landscape in the Medical Cannabis Industry

At global scale‚ the medical cannabis market is a mixture of existing pharmaceutical companies and cannabis companies‚ where market share is consolidated by pooling resources‚ intellectual property‚ and brand equity‚ which continues to be driven by further investment in research and development to create reliable products with predictable outcomes․ They are also expanding as part of joint ventures or acquisitions‚ as well as educational outreach efforts to inform healthcare personnel and the general public about the medical benefits of cannabis․

Key Medical Cannabis Market Players Include:

• Apothecanna
• Aurora Cannabis Inc.
• Canopy Growth Corporation
• Crop King Seeds
• Curaleaf Laboratories
• Jazz Pharmaceuticals Inc.
• Little Green Pharma
• Mary's Nutritionals, LLC
• Medical Marijuana Inc.
• The Cronos Group
• Tilray Brands Inc.

Recent Developments in the Medical Cannabis Market

• Canopy Growth Corporation (2020): Entered a strategic partnership with Acreage Holdings, Inc., a U.S.-based cannabis operator, structured to allow Canopy Growth to acquire Acreage once cannabis becomes federally legal in the United States — positioning the company for future growth in the U.S. cannabis market.
• Jazz Pharmaceuticals (2021): Acquired GW Pharmaceuticals, enabling Jazz Pharmaceuticals to expand its product portfolio into cannabinoid-based therapies and bolster its presence in the neurology and rare disease markets.
• Aurora Cannabis Inc. (2021): Completed a strategic business transformation plan involving various cost-saving initiatives, restructuring, and divestitures to improve financial performance and focus on its core businesses.

Key Regional Insight: North America's Strategic Position

North America is a highly developed and rapidly growing medical market with pro-cannabis regulations‚ relatively high levels of awareness among patients and consumers‚ and an effective healthcare infrastructure․ The United States and Canada continue to lead the world in legal access‚ patient adoption‚ and institutional investment․ Regional health services are increasingly prescribing cannabis-based medicinal products for use in chronic pain‚ cancer treatments and neurological conditions․ The existing e-commerce infrastructure and networks are able to support commercial cannabis product distribution by dispensaries․ Policy drivers also include political reform at the federal level in the USA‚ which could stimulate further market development and investment opportunities for global pharmaceutical companies․

Market Drivers, Challenges & Opportunities

Major Market Drivers:

• Expanding legalization and regulatory acceptance of medical cannabis globally.
• Growing prevalence of chronic pain, cancer, and neurological disorders driving patient demand.
• Rising investments in cannabis R&D and standardized pharmaceutical product development.
• Increasing demand for natural and plant-based alternatives to traditional pharmaceuticals.

Key Challenges:

Regulatory inconsistencies and complex compliance requirements across different jurisdictions.

Stigma and lack of awareness among certain patient demographics and healthcare professionals.

Supply chain disruptions and quality control concerns in emerging markets.

Emerging Opportunities:

• Exploration of medical cannabis for gastrointestinal disorders and substance use disorder treatment.
• Rising consumer preference for CBD-based products with minimal psychoactive effects.
• Expansion into under-penetrated markets in Asia Pacific, Latin America, and the Middle East.
• Technological advancements in drug delivery systems improving dosing precision and patient outcomes.

Conclusion: Medical Cannabis Market Outlook to 2034

The medical cannabis market is expected to continue growing globally until 2034‚ mainly due to the increased level of legalization‚ supporting clinical evidence‚ and continued development of pharmaceutical-grade cannabis products․ Cannabinoids are expected to gain increased acceptance as a viable treatment by healthcare systems internationally for cancer‚ chronic pain‚ epilepsy and other neurological disorders resulting in increased clinical usage․

As North America continues to lead the world and medical legalization continues to accelerate throughout emerging markets in the Asia Pacific and Europe‚ the medical cannabis market continues to grow and is expected to eventually expand globally as science‚ policy and patient preferences evolve․

About the Author:

IMARC Group is a leading global market research company providing data-driven insights and expert consulting services to businesses seeking to achieve their strategic objectives. With a multi-disciplinary team of industry experts, IMARC delivers thorough, reliable market intelligence across sectors including Technology, Construction, Healthcare, Energy, Food & Beverages, and more.

Media & Sales Contact

IMARC Group

United States: +1-201-971-6302

India: +91-120-433-0800

United Kingdom: +44-753-714-6104